Uncategorized

As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger

Published

on

While both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be more mixed.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version